Methyl iodide → HCID 58541893、化合物
反応式
[Br:1][C:2]1[CH:25]=[CH:24][C:5]2[N:6]([C:20]([CH3:23])([CH3:22])[CH3:21])[C:7]([C:9]3[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=3[C:15]3[N:16]=[N:17][NH:18][N:19]=3)=[N:8][C:4]=2[CH:3]=1.IC.[C:28]([O-])([O-])=O.[K+].[K+]>CN(C=O)C.CCOC(C)=O>[Br:1][C:2]1[CH:25]=[CH:24][C:5]2[N:6]([C:20]([CH3:22])([CH3:21])[CH3:23])[C:7]([C:9]3[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=3[C:15]3[N:16]=[N:17][N:18]([CH3:28])[N:19]=3)=[N:8][C:4]=2[CH:3]=1参加物
6
実験手順
To a vial is added 5-bromo-1-tert-butyl-2-[2-(2H-tetrazol-5-yl)-phenyl]-1H-benzimidazole (158 mg, 0.4 mmol) in DMF (5 mL), followed by the addition of iodomethane (114 mg, 0.8 mmol) and K2CO3 (110 mg, 0.8 mmol). The reaction mixture is stirred at room temperature for 0.5 hour. The reaction mixture is diluted with EtOAc, washed with water then, brine, dried with Na2SO4, filtered and concentrated. The residue is loaded to a silica gel column. The column is eluted with 0-3% MeOH/CH2Cl2. The product fractions are collected and is concentrated to afford 5-bromo-1-tert-butyl-2-[2-(2-methyl-2H-tetrazol-5-yl)-phenyl]-1H-benzimidazole (62 mg, 38%). LCMS (ESMS): m/z 411.59, 413.47 (M++1)
後処理
- washwashed with water
- dry with materialbrine, dried with Na2SO4
- filtrationfiltered
- concentrationconcentrated
- washThe column is eluted with 0-3% MeOH/CH2Cl2
- customThe product fractions are collected
- concentrationis concentrated
出典と根拠
- ORDレコード
- ord-d2a3c07509164658b7a699539aa50083
- 出典データセット
- uspto-grants-2013_04
- 特許番号
- US08420655B2
反応ノート
読み込み中…